<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167414</url>
  </required_header>
  <id_info>
    <org_study_id>URCC 8700</org_study_id>
    <nct_id>NCT00167414</nct_id>
  </id_info>
  <brief_title>Study for Using Radiosurgery on Limited Metastases of Breast Cancer</brief_title>
  <official_title>A Phase II Study for Using Radiosurgery on Limited Metastases of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether radiosurgery, along with standard
      chemotherapy, immunotherapy (the treatment of cancer by modulating the immune system and
      immune response), or hormonal therapy, affects the quality and length of life. The standard
      therapy is surgery, radiation therapy, or chemotherapy alone or in any combination. A second
      purpose of this study is to determine if the levels of a special type of protein (called
      cytokines) found in the blood are related to the quality of life while on this treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before treatment begins, you will have a physical exam and blood tests. Physical evaluations
      and blood tests will be done each week while you are receiving treatment, and at follow-up
      visits. You will be seen for follow-up evaluations 4 weeks after treatment is completed, and
      every three months thereafter. You will be asked to fill out a Quality of Life questionnaire,
      which should take 5-10 minutes to complete. This will be done prior to treatment and at your
      follow-up visits. You will receive high dose radiation therapy directed at the site of
      metastasis. This treatment will be given once a day, 5 times a week (Monday through Friday)
      for one to four weeks depending on the location and size of the disease to be treated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2000</start_date>
  <completion_date type="Actual">November 1, 2016</completion_date>
  <primary_completion_date type="Actual">November 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The percent of patients that survived from date of enrollment until 2 year follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 years</time_frame>
    <description>The percent of patients that survived from date of enrollment until 4 year follow-up visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 years</time_frame>
    <description>The percent of patients that survived from date of enrollment until 6 year follow-up visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With Lesion Local Control</measure>
    <time_frame>6 years</time_frame>
    <description>Lesion local failure was scored as an event if any treated lesion increased by greater than or equal to 20% using the Response Evaluation Criteria in Solid Tumors criteria or local failure was confirmed pathologically. Lesion control includes all participants that did not fall into the category of lesion failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced a Grade 4 or 5 Toxicity</measure>
    <time_frame>6 years</time_frame>
    <description>Number of participants who experienced a grade 4 or 5 toxicity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Breast Cancer, Metastatic</condition>
  <arm_group>
    <arm_group_label>Hypofractionated Stereotactic Body Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypofractionated Stereotactic Body Radiation Therapy</intervention_name>
    <description>Hypofractionated Stereotactic Body Radiation Therapy</description>
    <arm_group_label>Hypofractionated Stereotactic Body Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Stereotactic Body Radiation Therapy</intervention_name>
    <description>Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.</description>
    <arm_group_label>Hypofractionated Stereotactic Body Radiation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: no limit

          -  Karnofsky performance status (KPS) â‰¥ 70

          -  No more than 5 metastatic sites involving one or more different organs (liver, lung or
             bone).

          -  The size of the lesion must be such that it can be safely treated to sterilizing
             radiation doses according to the rules in the protocol.

          -  Previously treated lesions are not eligible unless the prescribed dose can be safely
             delivered.

          -  Concurrent therapy is allowed and recommended. The chemotherapy protocol type and
             schedule are at the discretion of the medical oncologist.

          -  Informed consent must be obtained.

          -  Pregnancy test must be negative for women of child bearing potential

        Exclusion Criteria:

          -  Inability of patient to be followed longitudinally as specified by protocol.

          -  Technical inability to achieve required dose based on safe dose constraints required
             for radiosurgery.

          -  Women who are pregnant or nursing.

          -  Failure to meet requirements in Inclusion Criteria

          -  Contraindications to radiation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Radiation Oncology: University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://radonc.urmc.rochester.edu/novalis_brochure/breast_mets_study.html</url>
    <description>Click here for more information about this study: Using Radiosurgery On Limited Metastases Of Breast Cancer</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>October 10, 2017</results_first_submitted>
  <results_first_submitted_qc>December 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2018</results_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Hong Zhang</investigator_full_name>
    <investigator_title>Assistant Professor Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>conformal radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hypofractionated Stereotactic Body Radiation Therapy</title>
          <description>Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hypofractionated Stereotactic Body Radiation Therapy</title>
          <description>Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>The percent of patients that survived from date of enrollment until 2 year follow-up visit.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Stereotactic Body Radiation Therapy</title>
            <description>Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The percent of patients that survived from date of enrollment until 2 year follow-up visit.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>The percent of patients that survived from date of enrollment until 4 year follow-up visit</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Stereotactic Body Radiation Therapy</title>
            <description>Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The percent of patients that survived from date of enrollment until 4 year follow-up visit</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>The percent of patients that survived from date of enrollment until 6 year follow-up visit</description>
        <time_frame>6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Stereotactic Body Radiation Therapy</title>
            <description>Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The percent of patients that survived from date of enrollment until 6 year follow-up visit</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With Lesion Local Control</title>
        <description>Lesion local failure was scored as an event if any treated lesion increased by greater than or equal to 20% using the Response Evaluation Criteria in Solid Tumors criteria or local failure was confirmed pathologically. Lesion control includes all participants that did not fall into the category of lesion failure.</description>
        <time_frame>6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Stereotactic Body Radiation Therapy</title>
            <description>Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Lesion Local Control</title>
          <description>Lesion local failure was scored as an event if any treated lesion increased by greater than or equal to 20% using the Response Evaluation Criteria in Solid Tumors criteria or local failure was confirmed pathologically. Lesion control includes all participants that did not fall into the category of lesion failure.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced a Grade 4 or 5 Toxicity</title>
        <description>Number of participants who experienced a grade 4 or 5 toxicity</description>
        <time_frame>6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Stereotactic Body Radiation Therapy</title>
            <description>Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced a Grade 4 or 5 Toxicity</title>
          <description>Number of participants who experienced a grade 4 or 5 toxicity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hypofractionated Stereotactic Body Radiation Therapy</title>
          <description>Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy
Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>nonmalignant pleural and pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hong Zhang</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-341-6750</phone>
      <email>hong_zhang@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

